VRTX vs MRNA — Key Metrics

Metric VRTX (VERTEX PHARMACEUTICALS INC) MRNA (MODERNA INC)
Price536.45196.79
Market Cap136.01 Billion79.63 Billion
P/E (TTM)34.23-27.8
P/B (Quarterly)6.43615.043
P/S (TTM)10.531.53
Net Profit Margin (TTM)30.7-110.5
Gross Margin (TTM)85.528.0
ROE (TTM)20.1-37.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

VERTEX PHARMACEUTICALS INC
vs
 
MODERNA INC
 
VERTEX PHARMACEUTICALS INC
vs
 
MODERNA INC
Performance Comparison
AI Model Recommendation
VRTX · VERTEX PHARMACEUTICALS INC

Outperform

42
UnderperformOutperform
MRNA · MODERNA INC

Greatly Underperform

-94
UnderperformOutperform
Recommendation Summary

Stock VRTX is projected to outperform the market, stock MRNA is projected to greatly underperform the market. Upfront Recommendation: VRTX.

Financial Metrics
Prices delayed ~15 min
VRTX Metrics MRNA
$536.45 Price $196.79
— Market Capitalization —
10.5 Price to Sales 31.53
12.28 Price to Gross Profit 112.62
32.0 Price to R&D 29.96
11.64 Price to Current Assets 10.84

VRTX vs MRNA at a glance

Vertex Pharmaceuticals INC (VRTX) and Moderna INC (MRNA) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $79.6 billion for MRNA, about 1.7 times the size.

On trailing-twelve-month figures, VRTX trades at 10.5 times trailing sales and MRNA at 31.5; net profit margins are 30.7% and -110.5%.

The Upfront Investment model currently rates VRTX Outperform and MRNA Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.